Website
News25/Ratings8
News · 26 weeks220%
2025-10-262026-04-19
Mix590d
- SEC Filings2(40%)
- Analyst1(20%)
- Earnings1(20%)
- Other1(20%)
Latest news
25 items- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T PlatformNEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today highlights the interim futility analysis announced by Allogene Therapeutics, Inc. ("Allogene") from Allogene's sponsored pivotal ALPHA3 trial evaluating cema-cel in first-line consolidation for large B-cell lymphoma (LBCL). Cema-cel is a product candidate licensed to Servier under the License, Development and Commercialization Agreement signed by and between les Laboratoires Servier and Institut de Recherches Internationales Servier ("Servier") and Cellectis (the "Serv
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") ((Euronext Growth: ALCLS, NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 20, 2026, at 8:00 AM ET / 1:00 PM CET. The call will include the Company's fourth quarter and full year 2025 results and an update on business activities. Details for the call are
- ANALYSTJefferies resumed coverage on Cellectis with a new price targetJefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Announces 2026 Strategy and CatalystsNEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026. "2025 was a transformational year for Cellectis, as we transitioned to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel." said André Choulika, Ph.D., Chief Executive Officer of Cellectis. "As we enter 2026, we remain fully committed to executing our pivotal Phase 2 BALLI-01 trial for lasme-cel in ALL, with interim data expected in Q4, presen
- PRAllogene Therapeutics Reports Favorable Result for Servier in Arbitration with CellectisArbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the f
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Announces Arbitral Decision in Dispute with ServierNEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL ("Servier"), relating to the License, Development and Commercialization Agreement entered into between Servier and Cellectis on March 6, 2019, as amended (the "License Agreement"). The Tribunal ruled on a partial termination of the License Agreement with respect to product UCART19 V1 (also refer
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Cellectis S.A.SCHEDULE 13D/A - Cellectis S.A. (0001627281) (Subject)
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHLEti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistenceIL-2 cohort enrollment to start in Q1 2026; full Phase 1 dataset expected in 2026 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced the presentation of encouraging updated data of patients treated in the Phase 1 NATHALI-01 clinical trial with eti-cel, at the 67th Annual Meeting of the American Society of He
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem CellsNEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes an article in Nature Communications establishing circular single-stranded DNA (CssDNA) as a highly efficient non-viral DNA donor template, for gene insertion in hematopoietic stem and progenitor cells (HSPCs). Gene editing of HSPCs offers the potential for long-term therapeutic benefit. While viral vectors such as AAV6 are commonly used for gene insertion, they raise safety and efficacy concerns. Over the past decade, non-viral DNA templates delivery has emerged
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis Reports Third Quarter 2025 Financial Results and Provides Business UpdatePresented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi First interim analysis for the BALLI-01 trial expected in Q4 2026 Eti-cel in r/r NHL (NATHALI-01) ORR of 86% and 57% CR rate (n=7)Development update to be presented at the ASH 2025 annual meetingFull Phase 1 dataset expected to be shared in 2026 Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025Cash,
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis to Present a Development Update for eti-cel at ASH 2025Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor activity in patients with r/r NHLEti-cel full Phase 1 dataset, including low-dose IL-2 combination cohorts, expected to be presented in 2026Correlation between alemtuzumab exposure and response with lasme-cel (UCART22) allows optimization of efficacy without an increase in toxicities NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-e
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis to Report Third Quarter Financial Results on November 7, 2025NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com About CellectisC
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)
- PRCellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 IEC-HS which resolved) ○ Durability: in patients who achieved MRD-negative CR/CRi, median OS was 14.8 months ○ In the target Phase 2 population, CR/CRi rate of 56% with ~80% of patients achieving MRD-negative status ○ In the target Phase 2 population, 100% patients became transplant eligible with 78% proceeding to transplant ○ Among 11 patients previously treated with all 3 targeted therapies (inotuzumab, blinatumomab, and CD19 CAR-T), 8 responded and 7 achieved MRD-neg
- SECSEC Form 6-K filed by Cellectis S.A.6-K - Cellectis S.A. (0001627281) (Filer)